相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition
Agata Okonska et al.
MOLECULAR CANCER THERAPEUTICS (2020)
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Duo Xu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer
Matthieu Lacroix et al.
MOLECULAR METABOLISM (2020)
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
Daniel Rathkey et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus
Tiphaine Delaunay et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer
Haitang Yang
JOURNAL OF THORACIC ONCOLOGY (2020)
The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy
Haitang Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tumour heterogeneity and the evolutionary trade-offs of cancer
Jean Hausser et al.
NATURE REVIEWS CANCER (2020)
APID database: redefining protein-protein interaction experimental evidences and binary interactomes
Diego Alonso-Lopez et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2019)
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy
Megan M. Tu et al.
SCIENCE ADVANCES (2019)
Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
Ursula Bommhardt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling
Jiao Wu et al.
NATURE (2019)
Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss
Hongyu Ding et al.
CELL REPORTS (2019)
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Haitang Yang et al.
ONCOGENESIS (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat et al.
ANNALS OF ONCOLOGY (2019)
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
Duo Xu et al.
CANCERS (2019)
Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis
Dana Ishay-Ronen et al.
CANCER CELL (2019)
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
Alice Guazzelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Drugging in the absence of p53
Obed Akwasi Aning et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Muhammad Umair Mushtaq et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Robert F. H. Walter et al.
JOURNAL OF ONCOLOGY (2018)
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Luciano Mutti et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
Ankur Chakravarthy et al.
NATURE COMMUNICATIONS (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
SETD2 mutations in primary central nervous system tumors
Angela N. Viaene et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
Kun Tian et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis
Julian Musa et al.
CELL DEATH & DISEASE (2017)
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
Loredana Urso et al.
ONCOTARGET (2017)
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
Masayuki Yamaji et al.
CANCER MEDICINE (2017)
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
Mara A. Bonelli et al.
NEOPLASIA (2017)
Oncolytic viral Therapy for Mesothelioma
Daniel F. Pease et al.
FRONTIERS IN ONCOLOGY (2017)
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells
Astero Klampatsa et al.
CANCER LETTERS (2017)
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Matthew G. Rees et al.
NATURE CHEMICAL BIOLOGY (2016)
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Toshiro Moroishi et al.
CELL (2016)
Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression
Yuhao Shi et al.
DEVELOPMENTAL CELL (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
SETD2: an epigenetic modifier with tumor suppressor functionality
Jun Li et al.
ONCOTARGET (2016)
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer
Ran Zhao et al.
EBIOMEDICINE (2016)
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
Guangwu Guo et al.
CANCER RESEARCH (2015)
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou et al.
BRITISH JOURNAL OF CANCER (2014)
Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma
Paola Indovina et al.
CANCER BIOLOGY & THERAPY (2014)
Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma
Domenico Di Marzo et al.
CELL CYCLE (2014)
Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma
Fabian D. Mairinger et al.
FUTURE ONCOLOGY (2014)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Identification of potential synthetic lethal genes to p53 using a computational biology approach
Xiaosheng Wang et al.
BMC MEDICAL GENOMICS (2013)
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
R. Mezzapelle et al.
BRITISH JOURNAL OF CANCER (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
Yan Yang et al.
BLOOD (2012)
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon et al.
CELL (2012)
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601) A Brief Report
Arkadiusz Z. Dudek et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Regulation of lipid metabolism by p53-fighting two villains with one sword
Ido Goldstein et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
ROS-Mediated p53 Induction of Lpin1 Regulates Fatty Acid Oxidation in Response to Nutritional Stress
Wissam Assaily et al.
MOLECULAR CELL (2011)
PGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress
Nirmalya Sen et al.
MOLECULAR CELL (2011)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study
Linda L. Garland et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR overexpression in malignant pleural mesothelioma - An immunohistochemical and molecular study with clinico-pathological correlations
A Destro et al.
LUNG CANCER (2006)
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth
DA Altomare et al.
ONCOGENE (2005)
Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B
R Govindan et al.
CLINICAL CANCER RESEARCH (2005)
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression
GH Xiao et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines
S Toma et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
分享论文
